Patents Assigned to Medlmmune, LLC
  • Publication number: 20120135023
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Application
    Filed: December 16, 2011
    Publication date: May 31, 2012
    Applicant: Medlmmune, LLC
    Inventors: Chin-Fen Yang, George Kemble, Chongguang Liu
  • Publication number: 20120027797
    Abstract: This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes.
    Type: Application
    Filed: October 12, 2011
    Publication date: February 2, 2012
    Applicant: Medlmmune, LLC
    Inventor: Vu Truong-Le
  • Publication number: 20110287022
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognoses to patients having IFN?-induced disorders.
    Type: Application
    Filed: June 19, 2009
    Publication date: November 24, 2011
    Applicant: Medlmmune, LLC
    Inventors: Yihong Yao, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener, Barbara White
  • Publication number: 20110243929
    Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.
    Type: Application
    Filed: December 17, 2010
    Publication date: October 6, 2011
    Applicant: Medlmmune, LLC
    Inventors: Anthony COYLE, Yihong Yao, Bahija Jallal, Gianluca Carlesso, Michael Bowen
  • Publication number: 20110243996
    Abstract: This invention provides methods and compositions to preserve bioactive materials, such as peptides, nucleic acids, viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for intranasal administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles for intranasal administration.
    Type: Application
    Filed: April 1, 2011
    Publication date: October 6, 2011
    Applicants: Medlmmune, LLC, The Regents of the University of Colorado
    Inventors: Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
  • Publication number: 20110033378
    Abstract: Cysteine engineered antibodies useful for the site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such antibodies are also provided.
    Type: Application
    Filed: January 16, 2009
    Publication date: February 10, 2011
    Applicant: Medlmmune, LLC.
    Inventors: Nazzareno Dimasi, Changshou Gao, Herren Wu
  • Publication number: 20110008329
    Abstract: The present invention provides methods for managing, treating and/or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), and/or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and/or wheezing and/or COPD in said patient.
    Type: Application
    Filed: June 25, 2008
    Publication date: January 13, 2011
    Applicant: Medlmmune, LLC
    Inventors: Subramaniam Krishnan, JoAnn Suzich, Peter Kiener, Genevieve Losonsky, Herren Wu, William Dall'Acqua, Bettina Richter
  • Publication number: 20100330162
    Abstract: This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles.
    Type: Application
    Filed: September 1, 2010
    Publication date: December 30, 2010
    Applicants: Medlmmune, LLC, The Regents of the University of Colorado, a body corporation
    Inventors: Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
  • Publication number: 20100278929
    Abstract: The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such methods provide formulations that offer multiple advantages over formulations produced by non-optimized methods including less stringent or more readily available transportation/storage conditions, and less frequent dosing or smaller dosage amounts in the therapeutic, prophylactic and diagnostic use of such formulations. The invention further provides methods of utilizing the formulations of the present invention.
    Type: Application
    Filed: January 19, 2010
    Publication date: November 4, 2010
    Applicant: Medlmmune, LLC
    Inventors: Ziping Wei, Guillermo Tous, Mark Schenerman, Christian B. Allan
  • Publication number: 20100196385
    Abstract: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.
    Type: Application
    Filed: September 18, 2009
    Publication date: August 5, 2010
    Applicant: Medlmmune LLC
    Inventors: Vahe Bedian, David Jenkins, Ian Foltz
  • Publication number: 20100196388
    Abstract: The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.
    Type: Application
    Filed: September 18, 2009
    Publication date: August 5, 2010
    Applicant: Medlmmune LLC
    Inventors: David Jenkins, Neil Michaud, Naomi Laing, Jaspal Singh Kang
  • Publication number: 20100167270
    Abstract: The invention relates to improved strains of mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention further relates to methods for propagating mammalian MPV in the absence of trypsin. The methods and compositions of the invention can be used for the preparation of vaccines against, e.g., MPV infections.
    Type: Application
    Filed: December 17, 2009
    Publication date: July 1, 2010
    Applicant: Medlmmune,LLC
    Inventor: Jeanne H. Schickli
  • Publication number: 20090277254
    Abstract: The invention provides methods of improving packed bed chromatography performance.
    Type: Application
    Filed: May 8, 2009
    Publication date: November 12, 2009
    Applicant: Medlmmune, LLC
    Inventors: Brad M. Matanin, David A. Page
  • Publication number: 20090208532
    Abstract: Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided.
    Type: Application
    Filed: February 12, 2009
    Publication date: August 20, 2009
    Applicant: Medlmmune, LLC
    Inventors: Qi Dang, Richard Schwartz
  • Publication number: 20090186038
    Abstract: The present invention provides prophylactic an therapeutic protocols designed to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managing, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present invention encompasses combination therapies, pharmaceutical compositions, articles of manufacture, and kits.
    Type: Application
    Filed: February 24, 2009
    Publication date: July 23, 2009
    Applicant: Medlmmune, LLC
    Inventor: Jennifer Lynne Reed
  • Publication number: 20090175898
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Application
    Filed: October 31, 2008
    Publication date: July 9, 2009
    Applicant: Medlmmune, LLC
    Inventors: Chin-Fen Yang, George Kemble, Chongguang Liu
  • Publication number: 20080279851
    Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.
    Type: Application
    Filed: May 7, 2008
    Publication date: November 13, 2008
    Applicant: Medlmmune, LLC
    Inventors: Anthony COYLE, Yihong Yao, Bahija Jallal, Gianluca Carlesso, Michael Bowen